<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-130642" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Neuromyelitis Optica Spectrum Disorder (NMOSD)</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Shumway</surname>
            <given-names>Caleb L.</given-names>
          </name>
          <aff>Gavin Herbert Eye Institute, UC-Irvine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Bhupendra C.</given-names>
          </name>
          <aff>University of Utah</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Tripathy</surname>
            <given-names>Koushik</given-names>
          </name>
          <aff>ASG Eye Hospital, BT Road, Kolkata, India</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>De Jesus</surname>
            <given-names>Orlando</given-names>
          </name>
          <aff>University of Puerto Rico, Medical Sciences Campus, Neurosurgery Section</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Caleb Shumway declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Bhupendra Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Koushik Tripathy declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Orlando De Jesus declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>8</day>
          <month>1</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-130642.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Neuromyelitis optica spectrum disorder (NMOSD) is an uncommon yet impactful inflammatory and demyelinating disorder of the central nervous system. NMOSD primarily targets the optic nerves, brainstem, and spinal cord, presenting a unique set of challenges for diagnosis and management. This disorder, comprising six syndromes, is intricately linked to aquaporin-4 immunoglobulin G antibodies (AQP4-IgG), necessitating serologic testing for accurate evaluations. This course will delve into the diverse clinical manifestations of NMOSD, emphasizing the importance of distinguishing between AQP4-IgG seropositive and seronegative patients. Core clinical features, such as optic neuritis, transverse myelitis, brainstem syndrome, and area postrema syndrome,&#x000a0;are thoroughly explored to enhance diagnostic precision.</p>
        <p>The focus extends to the treatment paradigm, which often involves chronic immunosuppressive therapy to prevent long-term optic nerve damage and relapse. The course provides a comprehensive understanding of the evaluation and management of NMOSD, equipping healthcare professionals with the knowledge and skills necessary to optimize patient care. Throughout the activity, the significance of the interprofessional team in evaluating and treating patients with NMOSD&#x000a0;is underscored. Collaborative efforts among healthcare professionals ensure a holistic approach to managing this complex disorder.&#x000a0;</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Determine the etiology, epidemiology, pathophysiology, and histopathology of neuromyelitis optica spectrum disorder.</p></list-item><list-item><p>Identify the clinical features and improve evaluation of patients with neuromyelitis optica spectrum disorder.</p></list-item><list-item><p>Determine the differential diagnoses, complications, management, and prognosis of neuromyelitis optica spectrum disorder.</p></list-item><list-item><p>Implement effective collaboration and communication among interprofessional team members to improve outcomes and treatment efficacy for patients with&#x000a0;neuromyelitis optica spectrum disorder, including&#x000a0;coordinating a comprehensive care plan.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=130642&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=130642">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-130642.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Neuromyelitis optica spectrum disorder (NMOSD), previously called neuromyelitis optica or Devic disease, was first described by Dr. Eugene Devic in 1894 while evaluating a patient with optic neuritis with accompanying neuromuscular manifestations (see <bold>Image&#x000a0;1.</bold>&#x000a0;Neuromyelitis Optica). That same year,&#x000a0;Fernand Gault, Dr. Devic&#x02019;s student, published his doctoral thesis presenting&#x000a0;a literature review of previous medical cases, including the&#x000a0;clinicopathological findings of Dr. Devic&#x02019;s case.<xref ref-type="bibr" rid="article-130642.r1">[1]</xref>&#x000a0;Multiple sclerosis (MS)&#x000a0;was the most prevalent identifiable autoimmune disease causing optic neuritis for many years. Recent discoveries have highlighted rarer, more sinister&#x000a0;autoimmune diseases manifesting with optic neuritis, such as neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody disease (MOGAD).<xref ref-type="bibr" rid="article-130642.r2">[2]</xref></p>
        <p>In recent years, the definition of neuromyelitis optica has been expanded as a specific antibody was discovered in the serum of affected patients, and various manifestations have&#x000a0;been recognized in a spectrum of diseases. Because of this, the term neuromyelitis optica spectrum disorder is now used to include optic neuritis with spinal cord manifestations and other neurologic disorders associated with the serum aquaporin-4 immunoglobulin G antibodies (AQP4-IgG).<xref ref-type="bibr" rid="article-130642.r3">[3]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-130642.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>The etiology of NMOSD is still unclear. In the past, NMOSD was considered a variant of MS, but recent studies have elucidated the differences in the disease process, manifestations, and management. Whole-genome sequencing has identified some at-risk genotypes for NMOSD, and major histocompatibility complexes (including&#x000a0;<italic toggle="yes">HLA-DRB1</italic>*03:01) have been identified.<xref ref-type="bibr" rid="article-130642.r4">[4]</xref>&#x000a0;The genetic variant of major histocompatibility complexes of NMOSD is&#x000a0;more similar to systemic lupus erythematosus (SLE) than MS.<xref ref-type="bibr" rid="article-130642.r4">[4]</xref></p>
      </sec>
      <sec id="article-130642.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>The prevalence of NMOSD is approximately 0.3 to 4.4 per 100,000 people.<xref ref-type="bibr" rid="article-130642.r5">[5]</xref>&#x000a0;NMOSD&#x000a0;characteristically occurs in females (80%) and younger patients between 30 and&#x000a0;40 years of age.<xref ref-type="bibr" rid="article-130642.r6">[6]</xref>&#x000a0;Pediatric cases of NMOSD are rare but have been reported occasionally, comprising less than 5% of cases.<xref ref-type="bibr" rid="article-130642.r7">[7]</xref>&#x000a0;NMOSD occurs worldwide, and most information on the disorder is limited to economically advantaged countries, likely due to the relative ease of access to magnetic resonance imaging (MRI) and targeted antibody testing compared to emerging countries.<xref ref-type="bibr" rid="article-130642.r8">[8]</xref>&#x000a0;Worldwide, NMOSD has a variable prevalence among demyelinating diseases, comprising only 1% to 2% in the United States and Italy but 13.7% in India and over 30% in Thailand.<xref ref-type="bibr" rid="article-130642.r8">[8]</xref>&#x000a0;</p>
        <p>Ethnicity appears to play a role in the phenotype of the disease. Findings from a study in Cuba showed that African-heritage patients with NMOSD were older, had more lesions on MRI, and had more relapses&#x000a0;than comparable patients of other ethnicities.<xref ref-type="bibr" rid="article-130642.r9">[9]</xref>&#x000a0;The variations in the epidemiology of this disease should give the clinician additional information to consider the diagnosis of NMOSD, especially if a patient presents with a suspected demyelinating disease and is of Asian or Indian heritage or is older and of African descent.<xref ref-type="bibr" rid="article-130642.r10">[10]</xref>&#x000a0;NMOSD can correlate with autoimmune diseases such as systemic lupus erythematosus (SLE), celiac disease, Sj&#x000f6;gren syndrome, and&#x000a0;sarcoidosis.<xref ref-type="bibr" rid="article-130642.r11">[11]</xref>&#x000a0;NMOSD attacks have been shown to occur in 20% to 30% of cases after an environmental trigger, such as post-vaccination or infection.<xref ref-type="bibr" rid="article-130642.r12">[12]</xref><xref ref-type="bibr" rid="article-130642.r13">[13]</xref></p>
      </sec>
      <sec id="article-130642.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>NMOSD is an inflammatory disease that primarily affects the optic nerve and spinal cord; the brainstem, specifically the area postrema, can also be involved.<xref ref-type="bibr" rid="article-130642.r14">[14]</xref>&#x000a0;IgG antibodies against aquaporin-4&#x000a0;are noted in more than 60% to 90% (specificity 90%, sensitivity 70%-90%) of patients with NMOSD.<xref ref-type="bibr" rid="article-130642.r3">[3]</xref><xref ref-type="bibr" rid="article-130642.r15">[15]</xref><xref ref-type="bibr" rid="article-130642.r16">[16]</xref><xref ref-type="bibr" rid="article-130642.r17">[17]</xref><xref ref-type="bibr" rid="article-130642.r18">[18]</xref>&#x000a0;Aquaporin-4 is a transmembrane water channel found on the foot processes of astrocytes, and is highly concentrated in certain parts of the central nervous system, such as the optic nerve, the spinal cord, and the area postrema.<xref ref-type="bibr" rid="article-130642.r19">[19]</xref>&#x000a0;Circumventricular areas, including periaqueductal grey matter, are rich in AQP4 and are more involved in NMOSD.<xref ref-type="bibr" rid="article-130642.r18">[18]</xref>&#x000a0;NMOSD is an autoimmune demyelinating astrocytopathy where the AQP4-IgG mediates perivascular lymphocytic infiltration, leading to axonal loss&#x000a0;with a preference for the aforementioned at-risk areas.<xref ref-type="bibr" rid="article-130642.r20">[20]</xref></p>
      </sec>
      <sec id="article-130642.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Damage to the axons usually precedes demyelination in NMOSD.<xref ref-type="bibr" rid="article-130642.r17">[17]</xref>&#x000a0;Histopathological features include activation of microglia or macrophage cells, axonal damage, perivascular deposition of immunoglobulins (especially immunoglobulin M), eosinophilic infiltration, and local activation of the complement system.<xref ref-type="bibr" rid="article-130642.r21">[21]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-130642.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Optic neuritis&#x000a0;presents with acute onset, painful, monocular vision loss, with a relative afferent pupillary defect in the affected eye.<xref ref-type="bibr" rid="article-130642.r22">[22]</xref>&#x000a0;The clinical exam of a patient with acute optic neuritis should always&#x000a0;include the visual acuity, pupils, intraocular pressure, and&#x000a0;a thorough neuro-ophthalmic exam. A fundus exam will typically reveal optic nerve head elevation on the affected side. Recent literature highlights the less common but more sinister causes of optic neuritis, such as NMOSD or MOGAD; therefore, patients with acute optic neuritis should be specifically asked additional questions during the review of systems. If the patient suffers from intractable hiccups, unexplained nausea or vomiting, or symptomatic narcolepsy, NMOSD may be causing the optic neuritis.<xref ref-type="bibr" rid="article-130642.r3">[3]</xref><xref ref-type="bibr" rid="article-130642.r23">[23]</xref>&#x000a0;</p>
        <p>NMOSD may alternatively present less classically, and AQP4-IgG can also be present in other disorders (ie, isolated longitudinal extensive transverse myelitis, brainstem clinical manifestations, brainstem encephalitis, monophasic&#x000a0;optic neuritis, or recurrent optic neuritis).<xref ref-type="bibr" rid="article-130642.r11">[11]</xref>&#x000a0;A patient presenting with neurologic manifestations of brainstem lesions (and intractable hiccups, vomiting, or narcolepsy) should have a complete neurologic exam. Typically, simultaneous bilateral vision loss and paraplegia are noted due to bilateral optic neuritis with&#x000a0;transverse myelitis. However, optic neuritis and transverse myelitis may appear weeks apart.<xref ref-type="bibr" rid="article-130642.r21">[21]</xref>&#x000a0;</p>
        <p>NMOSD has been increasingly recognized as a non-monophasic illness; rather,&#x000a0;it follows a relapsing condition with events of disease exacerbation separated by years or decades.<xref ref-type="bibr" rid="article-130642.r17">[17]</xref>&#x000a0;Concurrent features of SLE, myasthenia gravis, autoimmune thyroid disease, Sj&#x000f6;gren&#x000a0;syndrome, and antiphospholipid antibody syndrome may be present.</p>
        <p>The core clinical characteristics of NMOSD for adult patients include the following:<xref ref-type="bibr" rid="article-130642.r3">[3]</xref>&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Optic neuritis</p>
          </list-item>
          <list-item>
            <p>Acute myelitis</p>
          </list-item>
          <list-item>
            <p>Area postrema syndrome (unexplained hiccups, nausea, or vomiting)</p>
          </list-item>
          <list-item>
            <p>Acute brainstem syndrome</p>
          </list-item>
          <list-item>
            <p>Symptomatic narcolepsy or acute diencephalic clinical syndrome with NMOSD-typical diencephalic MRI lesions&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Symptomatic cerebral syndrome with NMOSD-typical brain lesions</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-130642.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>NMOSD is evaluated by&#x000a0;clinical examination, serologic testing for the AQP4-IgG, and MRI with (and without) gadolinium.&#x000a0;Diagnosis is based on core clinical characteristics and supplemented by additional testing. The international consensus diagnostic criteria were&#x000a0;established in 2015, separating NMOSD into AQP4-IgG status (with testing, without testing, or unknown) and defining&#x000a0;clinical and MRI characteristics of NMOSD.<xref ref-type="bibr" rid="article-130642.r3">[3]</xref>&#x000a0;Color vision testing may show a decrease in color vision, and visual field (including Humphrey visual field)<xref ref-type="bibr" rid="article-130642.r24">[24]</xref> evaluation may show a central or centrocecal scotoma. Ancillary testing with optical coherence tomography can aid in the diagnosis and may reveal a thinner peripapillary nerve fiber layer than observed in MS cases.<xref ref-type="bibr" rid="article-130642.r25">[25]</xref></p>
        <p>MRI with and without gadolinium can assist in the evaluation of NMOSD. Characteristic findings in optic neuritis include white matter lesions and optic nerve enhancement (T2-hyperintense lesions or T1-weighted contrast-enhancing images).<xref ref-type="bibr" rid="article-130642.r3">[3]</xref>&#x000a0;Other MRI manifestations of NMOSD include acute myelitis, showing longitudinal intramedullary lesions or focal spinal cord atrophic segments.<xref ref-type="bibr" rid="article-130642.r3">[3]</xref>&#x000a0;The involvement of bilateral optic nerves, especially of the posterior optic nerve reaching as far as the optic chiasma, is very suggestive of NMOSD. In chronic stages, there is atrophy of the optic nerve and hyperintense signal on T2. The brain lesions in NMOSD may be preferentially located at the location of aquaporin-4 at peri-ependymal regions abutting the ventricles, including confluent periventricular sessile lesions and lesions at the medulla, dorsal pons, medial thalamus, hypothalamus, periaqueductal gray matter, and corpus callosum. The splenium of the corpus callosum may be diffusely involved and swollen. Corpus callosal lesions may have a marbled pattern due to heterogeneous&#x000a0;signals from overlapping lesions.<xref ref-type="bibr" rid="article-130642.r26">[26]</xref>&#x000a0;Patients with area postrema syndrome demonstrate lesions at the dorsal medulla region or area postrema. Those with acute brainstem syndrome show lesions at the peri-ependymal brainstem. Other brain imaging features include deep white matter lesions (punctate), large white matter lesions without mass effect (especially in pediatric and Black patients),&#x000a0;and corticospinal tract lesions (especially in Korean patients).<xref ref-type="bibr" rid="article-130642.r17">[17]</xref><xref ref-type="bibr" rid="article-130642.r27">[27]</xref><xref ref-type="bibr" rid="article-130642.r28">[28]</xref></p>
        <p>When MRI lesions show enhancement in the optic nerves and spinal cord, the main differential diagnosis of NMOSD is MS. It is important to distinguish these clinical entities as the prognosis and management differ considerably, and some MS drugs can worsen NMOSD.<xref ref-type="bibr" rid="article-130642.r29">[29]</xref><xref ref-type="bibr" rid="article-130642.r30">[30]</xref><xref ref-type="bibr" rid="article-130642.r31">[31]</xref>&#x000a0;In contrast with MS, NMOSD has some distinct radiologic features that differentiate the condition as a clinical entity. NMOSD shows longitudinal spinal cord lesions extending over 3 or more segments, while MS typically has short, multiple lesions.<xref ref-type="bibr" rid="article-130642.r27">[27]</xref>&#x000a0;However, around 14.5% of patients may have short transverse myelitis.<xref ref-type="bibr" rid="article-130642.r32">[32]</xref>&#x000a0;Bright spotty lesions in the central gray matter of the spinal cord that are very hyperintense on T2 (more than cerebrospinal fluid) and hypointense on T1 are specific for NMOSD. Acute lesions are usually enhanced&#x000a0;with gadolinium contrast in MRI.<xref ref-type="bibr" rid="article-130642.r32">[32]</xref><xref ref-type="bibr" rid="article-130642.r33">[33]</xref></p>
      </sec>
      <sec id="article-130642.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Due to the relative scarcity of NMOSD cases, consensus guidelines are challenging to establish. Most case series recommend a short course of immunosuppressive therapy (usually a corticosteroid), followed by chronic immunosuppressive therapy.<xref ref-type="bibr" rid="article-130642.r34">[34]</xref>&#x000a0;Treatment of the acute phase of NMOSD flare usually involves intravenous steroids such as methylprednisolone, often used in high doses (500-100 mg daily) for 5 to 10 days. Other studies advocate plasmapheresis treatment (55 mL/kg) and intravenous immunoglobulin.<xref ref-type="bibr" rid="article-130642.r35">[35]</xref><xref ref-type="bibr" rid="article-130642.r36">[36]</xref></p>
        <p>Chronic immunosuppressive therapy can be accomplished with azathioprine or rituximab as first-line agents.<xref ref-type="bibr" rid="article-130642.r17">[17]</xref> Second-line agents may include mycophenolate or methotrexate.<xref ref-type="bibr" rid="article-130642.r11">[11]</xref>&#x000a0;These second-line agents may be advantageous due to their infrequent dosing. Newer biologics are directed against specific immune mediators such as anti-IL-6, anti-complement, or anti-AQP4-IgG.<xref ref-type="bibr" rid="article-130642.r11">[11]</xref>&#x000a0;A retrospective multicenter analysis showed reductions in relapse rate with rituximab, mycophenolate, and azathioprine (with prednisone) of 88.2%, 87.4%, and 72.1%, respectively.<xref ref-type="bibr" rid="article-130642.r37">[37]</xref>&#x000a0;Differentiating MS from NMOSD is necessary as some drugs used for MS (including natalizumab and beta-interferon) may exacerbate NMOSD.<xref ref-type="bibr" rid="article-130642.r31">[31]</xref><xref ref-type="bibr" rid="article-130642.r38">[38]</xref></p>
      </sec>
      <sec id="article-130642.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnosis of a patient with optic neuritis typically includes MS, NMOSD, and MOGAD. MS is the most common of these entities and should be ruled out first. The clinician should be especially aware of the other 2 conditions, as they typically portend a&#x000a0;less favorable&#x000a0;prognosis and require different treatment.</p>
        <p>MOGAD is a rare disease associated with antibodies against myelin oligodendrocyte glycoprotein (MOG). MOGAD is usually monophasic (but recurrent optic neuritis may be noted) with a better prognosis than NMOSD. MOGAD has a lower female-to-male ratio or male predominance and is noted more often in childhood. Clinical presentations may&#x000a0;include features similar to acute disseminated encephalomyelitis (ADEM), optic neuritis, myelitis, and brainstem encephalitis. MRI features include bilateral anterior involvement of the optic nerve with long length, and the optic chiasma is less involved. The optic nerve head is usually swollen. In the spinal cord, a long segment of the conus or thoracolumbar spinal cord is usually affected. Contrast enhancement is infrequent. In the brain, MRI features include deep gray matter lesions, large lesions similar to ADEM, and&#x000a0;fluffy lesions in&#x000a0;cerebellar peduncles, pons, and around the fourth ventricle.&#x000a0;Lesions&#x000a0;of the peri-ependymal areas are rare. Up to 50% of patients with NMOSD or MOGAD can have a normal brain MRI at presentation.<xref ref-type="bibr" rid="article-130642.r39">[39]</xref></p>
        <p>Because NMOSD can also present without ocular symptoms, the presentation and differential of NMOSD broaden significantly when the patient does not have ocular involvement. Still, the primary clinical entity on the differential is MS, but theoretically, any lesion causing MS-like symptoms could be on the differential of NMOSD.</p>
        <p>Differences between NMOSD and MS include:<xref ref-type="bibr" rid="article-130642.r40">[40]</xref></p>
        <table-wrap id="article-130642.table0" position="float" orientation="portrait">
          <table style="width: 800px; border-color: black;" border="1" cellspacing="1" cellpadding="5">
            <tbody>
              <tr style="height: 13px;">
                <td style="height: 13px;" rowspan="1" colspan="1">
<bold>Features</bold>
</td>
                <td style="height: 13px;" rowspan="1" colspan="1">
<bold>NMOSD</bold>
</td>
                <td style="height: 13px;" rowspan="1" colspan="1">
<bold>MS</bold>
</td>
              </tr>
              <tr style="height: 13px;">
                <td style="height: 13px;" rowspan="1" colspan="1">Prevalence</td>
                <td style="height: 13px;" rowspan="1" colspan="1">Rare</td>
                <td style="height: 13px;" rowspan="1" colspan="1">Common</td>
              </tr>
              <tr style="height: 13px;">
                <td style="height: 13px;" rowspan="1" colspan="1">Female</td>
                <td style="height: 13px;" rowspan="1" colspan="1">80%&#x000a0;</td>
                <td style="height: 13px;" rowspan="1" colspan="1">&#x000a0;Around 66%<xref ref-type="bibr" rid="article-130642.r18">[18]</xref></td>
              </tr>
              <tr style="height: 13px;">
                <td style="height: 13px;" rowspan="1" colspan="1">&#x000a0;Age at presentation</td>
                <td style="height: 13px;" rowspan="1" colspan="1">&#x000a0;40 to 60 years</td>
                <td style="height: 13px;" rowspan="1" colspan="1">&#x000a0;20 to 40 years</td>
              </tr>
              <tr style="height: 26px;">
                <td style="height: 26px;" rowspan="1" colspan="1">Ethnic predisposition&#x000a0;&#x000a0;</td>
                <td style="height: 26px;" rowspan="1" colspan="1">&#x000a0;Asian and Black</td>
                <td style="height: 26px;" rowspan="1" colspan="1">&#x000a0;White</td>
              </tr>
              <tr style="height: 13px;">
                <td style="height: 13px;" rowspan="1" colspan="1">Bilateral&#x000a0;optic neuritis</td>
                <td style="height: 13px;" rowspan="1" colspan="1">Common&#x000a0;</td>
                <td style="height: 13px;" rowspan="1" colspan="1">Rare</td>
              </tr>
              <tr style="height: 26px;">
                <td style="height: 26px;" rowspan="1" colspan="1">Associated autoimmune diseases</td>
                <td style="height: 26px;" rowspan="1" colspan="1">&#x000a0;Usually none</td>
                <td style="height: 26px;" rowspan="1" colspan="1">May be present, including SLE, myasthenia gravis, autoimmune thyroid disease, Sj&#x000f6;gren&#x000a0;syndrome, antiphospholipid antibody syndrome</td>
              </tr>
              <tr style="height: 13px;">
                <td style="height: 13px;" rowspan="1" colspan="1">Severity of vision loss</td>
                <td style="height: 13px;" rowspan="1" colspan="1">Severe with little improvement</td>
                <td style="height: 13px;" rowspan="1" colspan="1">&#x000a0;Usually moderate visual loss with a good improvement of vision</td>
              </tr>
              <tr style="height: 13px;">
                <td style="height: 13px;" rowspan="1" colspan="1">Progressive course</td>
                <td style="height: 13px;" rowspan="1" colspan="1">Rare&#x000a0;</td>
                <td style="height: 13px;" rowspan="1" colspan="1">&#x000a0;Common</td>
              </tr>
              <tr style="height: 13px;">
                <td style="height: 13px;" rowspan="1" colspan="1">&#x000a0;Target tissue</td>
                <td style="height: 13px;" rowspan="1" colspan="1">White matter and grey matter</td>
                <td style="height: 13px;" rowspan="1" colspan="1">&#x000a0;White matter</td>
              </tr>
              <tr style="height: 13px;">
                <td style="height: 13px;" rowspan="1" colspan="1">Histopathology&#x000a0;</td>
                <td style="height: 13px;" rowspan="1" colspan="1">Cavitation or necrosis of tissue is common</td>
                <td style="height: 13px;" rowspan="1" colspan="1">Cavitation or necrosis of tissue is rare</td>
              </tr>
              <tr style="height: 13px;">
                <td style="height: 13px;" rowspan="1" colspan="1">Imaging of the spinal cord</td>
                <td style="height: 13px;" rowspan="1" colspan="1">
<p>Usually longitudinally extensive transverse myelitis (LETM)</p>
<p>Patchy, cloud-like enhancement on T1 images with contrast may be present</p>
<p>Involvement may extend to the medulla</p>
<p>Involvement of the central spinal cord, usually the cervicothoracic segment</p>
<p>Usually symptomatic</p>
</td>
                <td style="height: 13px;" rowspan="1" colspan="1">
<p>A short segment of the spinal cord is usually involved</p>
<p>The Peripheral spinal cord is usually involved&#x000a0;</p>
<p>May be asymptomatic</p>
</td>
              </tr>
              <tr style="height: 13px;">
                <td style="height: 13px;" rowspan="1" colspan="1">Imaging of brainstem</td>
                <td style="height: 13px;" rowspan="1" colspan="1">
<p>Involement of dorsal medulla/area postrema</p>
<p>The brainstem lesion may be contiguous with the spinal cord lesion</p>
</td>
                <td style="height: 13px;" rowspan="1" colspan="1">
<p>Clearly demarcated lesions anywhere in the brainstem</p>
<p>Any location may be involved, including ventral or dorsal pons</p>
</td>
              </tr>
              <tr style="height: 13px;">
                <td style="height: 13px;" rowspan="1" colspan="1">Imaging of brain</td>
                <td style="height: 13px;" rowspan="1" colspan="1">
<p>Involvement of the corpus callosum is uncommon</p>
<p>The thalamus, hypothalamus, and peri-ependymal 3rd ventricle region may be involved</p>
</td>
                <td style="height: 13px;" rowspan="1" colspan="1">
<p>Dawson fingers (periventricular lesions that are perpendicular to the border of the ventricle and that have a perivenular distribution, more prominent in T2 FLAIR images)</p>
<p>The lesions are distributed in time (both new and old lesions) and space (various areas involved [minimum of 2 locations]: typical areas are periventricular, juxtacortical, infratentorial, and the spinal cord)</p>
<p>Involvement of corpus callosum is common</p>
<p>Involvement of diencephalon is uncommon</p>
</td>
              </tr>
              <tr style="height: 13px;">
                <td style="height: 13px;" rowspan="1" colspan="1">Imaging of optic nerve</td>
                <td style="height: 13px;" rowspan="1" colspan="1">
<p>A long segment of the optic nerve (usually posterior) is usually involved.</p>
<p>May be bilateral or unilateral.</p>
</td>
                <td style="height: 13px;" rowspan="1" colspan="1">
<p>Usually, a short segment of the anterior optic nerve is involved</p>
<p>Usually unilateral</p>
</td>
              </tr>
              <tr style="height: 13px;">
                <td style="height: 13px;" rowspan="1" colspan="1">CSF analysis</td>
                <td style="height: 13px;" rowspan="1" colspan="1">
<p>Oligoclonal bands are rare</p>
<p>The protein content is higher than MS</p>
</td>
                <td style="height: 13px;" rowspan="1" colspan="1">
<p>Oligoclonal bands are seen frequently</p>
<p>The protein content is lower than MS</p>
</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
      <sec id="article-130642.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>NMOSD has a variable course and prognosis.<xref ref-type="bibr" rid="article-130642.r23">[23]</xref>&#x000a0;This condition is either relapsing (80% to 90%) or monophasic.<xref ref-type="bibr" rid="article-130642.r12">[12]</xref>&#x000a0;Some patients suffer from a chronic disability as a result of relapsing episodes. Study results have demonstrated that up to 22% of patients fully recover, while 7% do not show any recovery.<xref ref-type="bibr" rid="article-130642.r23">[23]</xref>&#x000a0;Individuals with relapsing NMOSD have a worse prognosis. Paraplegia or monoplegia is noted in around 52% of patients with relapsing disease compared to 31% of patients with monophasic disease occurrence.<xref ref-type="bibr" rid="article-130642.r13">[13]</xref>&#x000a0;Around 60% of patients with the relapsing disease are blind in 1 or both eyes compared to 22% of patients with the monophasic disease.<xref ref-type="bibr" rid="article-130642.r13">[13]</xref></p>
      </sec>
      <sec id="article-130642.s12" sec-type="Complications">
        <title>Complications</title>
        <p>Complications of NMOSD include visual field defects and motor impairment, with potential blindness and irreversible motor deficits.<xref ref-type="bibr" rid="article-130642.r41">[41]</xref>&#x000a0;In severe cases, myogenic respiratory failure is the cause of increased mortality.<xref ref-type="bibr" rid="article-130642.r23">[23]</xref></p>
      </sec>
      <sec id="article-130642.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patients&#x000a0;diagnosed with NMOSD should be educated on potential complications of the disorder, the comorbid-associated autoimmune conditions, and the importance of medication compliance and follow-up.<xref ref-type="bibr" rid="article-130642.r12">[12]</xref>&#x000a0;Currently, there are no known preventive strategies for NMOSD.</p>
      </sec>
      <sec id="article-130642.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The neuro-ophthalmologist is often initially involved in diagnosing patients with NMOSD, but patients may also initially present to a primary care provider or neurologist. It is essential to consult with an interprofessional team that includes the ophthalmologist, neurologist, radiologist, and primary care provider to provide adequate&#x000a0;care for these patients. The nurse's role is vital as these patients often require hospital admission with rapid induction of intravenous steroids. The pharmacist will be critical in adjusting the appropriate steroid dose for the patient while considering other conditions the patient may have. The radiologist is also key in d&#x000a0;appropriately&#x000a0;based on&#x000a0;MRI results. There aren't any large randomized clinical trials on diagnosing and treating NMOSD; therefore, reliance is primarily on consensus-based&#x000a0;expert opinion, and diagnostic criteria are based on historical, case-control studies.<xref ref-type="bibr" rid="article-130642.r3">[3]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-130642.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=130642&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=130642">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/neurology/neuromyelitis-optica-spectrum-disorder-nmosd/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=130642">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/130642/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=130642">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-130642.s16">
        <fig id="article-130642.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Neuromyelitis Optica. MRI showing inflammation of the spinal column, a common aspect of neuromyelitis optica. Contributed by Steve Lange, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="NMO" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-130642.s17">
        <title>References</title>
        <ref id="article-130642.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jarius</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wildemann</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>The history of neuromyelitis optica.</article-title>
            <source>J Neuroinflammation</source>
            <year>2013</year>
            <month>Jan</month>
            <day>15</day>
            <volume>10</volume>
            <fpage>8</fpage>
            <pub-id pub-id-type="pmid">23320783</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130642.r2">
          <label>2</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Guier</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Stokkermans</surname>
                <given-names>TJ</given-names>
              </name>
            </person-group>
            <chapter-title>Optic Neuritis</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>3</month>
            <day>26</day>
            <pub-id pub-id-type="pmid">32496733</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130642.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wingerchuk</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Banwell</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bennett</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Cabre</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Carroll</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Chitnis</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>de Seze</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fujihara</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Greenberg</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Jacob</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jarius</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lana-Peixoto</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Simon</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Tenembaum</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Traboulsee</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Waters</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wellik</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Weinshenker</surname>
                <given-names>BG</given-names>
              </name>
              <collab>International Panel for NMO Diagnosis</collab>
            </person-group>
            <article-title>International consensus diagnostic criteria for neuromyelitis optica spectrum disorders.</article-title>
            <source>Neurology</source>
            <year>2015</year>
            <month>Jul</month>
            <day>14</day>
            <volume>85</volume>
            <issue>2</issue>
            <fpage>177</fpage>
            <page-range>177-89</page-range>
            <pub-id pub-id-type="pmid">26092914</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130642.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Estrada</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Whelan</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Bronson</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Handsaker</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Carulli</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ransohoff</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>McCarroll</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Day-Williams</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Greenberg</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>MacArthur</surname>
                <given-names>DG</given-names>
              </name>
            </person-group>
            <article-title>A whole-genome sequence study identifies genetic risk factors for neuromyelitis optica.</article-title>
            <source>Nat Commun</source>
            <year>2018</year>
            <month>May</month>
            <day>16</day>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>1929</fpage>
            <pub-id pub-id-type="pmid">29769526</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130642.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Papadopoulos</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Verkman</surname>
                <given-names>AS</given-names>
              </name>
            </person-group>
            <article-title>Aquaporin 4 and neuromyelitis optica.</article-title>
            <source>Lancet Neurol</source>
            <year>2012</year>
            <month>Jun</month>
            <volume>11</volume>
            <issue>6</issue>
            <fpage>535</fpage>
            <page-range>535-44</page-range>
            <pub-id pub-id-type="pmid">22608667</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130642.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ransohoff</surname>
                <given-names>RM</given-names>
              </name>
            </person-group>
            <article-title>Illuminating neuromyelitis optica pathogenesis.</article-title>
            <source>Proc Natl Acad Sci U S A</source>
            <year>2012</year>
            <month>Jan</month>
            <day>24</day>
            <volume>109</volume>
            <issue>4</issue>
            <fpage>1001</fpage>
            <page-range>1001-2</page-range>
            <pub-id pub-id-type="pmid">22308524</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130642.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kitley</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Leite</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Nakashima</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Waters</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>McNeillis</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Takai</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Takahashi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Misu</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Elsone</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Woodhall</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>George</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Boggild</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vincent</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jacob</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fujihara</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Palace</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan.</article-title>
            <source>Brain</source>
            <year>2012</year>
            <month>Jun</month>
            <volume>135</volume>
            <issue>Pt 6</issue>
            <fpage>1834</fpage>
            <page-range>1834-49</page-range>
            <pub-id pub-id-type="pmid">22577216</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130642.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pandit</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Asgari</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Apiwattanakul</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Palace</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Paul</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Leite</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Kleiter</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Chitnis</surname>
                <given-names>T</given-names>
              </name>
              <collab>GJCF International Clinical Consortium &#x00026; Biorepository for Neuromyelitis Optica</collab>
            </person-group>
            <article-title>Demographic and clinical features of neuromyelitis optica: A review.</article-title>
            <source>Mult Scler</source>
            <year>2015</year>
            <month>Jun</month>
            <volume>21</volume>
            <issue>7</issue>
            <fpage>845</fpage>
            <page-range>845-53</page-range>
            <pub-id pub-id-type="pmid">25921037</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130642.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cabrera-G&#x000f3;mez</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Kurtzke</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Gonz&#x000e1;lez-Quevedo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lara-Rodr&#x000ed;guez</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>An epidemiological study of neuromyelitis optica in Cuba.</article-title>
            <source>J Neurol</source>
            <year>2009</year>
            <month>Jan</month>
            <volume>256</volume>
            <issue>1</issue>
            <fpage>35</fpage>
            <page-range>35-44</page-range>
            <pub-id pub-id-type="pmid">19224310</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130642.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Mealy</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schmidt</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ruprecht</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Paul</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ringelstein</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Aktas</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Hartung</surname>
                <given-names>HP</given-names>
              </name>
              <name>
                <surname>Asgari</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Tsz-Ching</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Siritho</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Prayoonwiwat</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Shin</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Hyun</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Leite</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Palace</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>HJ</given-names>
              </name>
            </person-group>
            <article-title>Racial differences in neuromyelitis optica spectrum disorder.</article-title>
            <source>Neurology</source>
            <year>2018</year>
            <month>Nov</month>
            <day>27</day>
            <volume>91</volume>
            <issue>22</issue>
            <fpage>e2089</fpage>
            <page-range>e2089-e2099</page-range>
            <pub-id pub-id-type="pmid">30366977</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130642.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Trebst</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Jarius</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Berthele</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Paul</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Schippling</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wildemann</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Borisow</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kleiter</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Aktas</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>K&#x000fc;mpfel</surname>
                <given-names>T</given-names>
              </name>
              <collab>Neuromyelitis Optica Study Group (NEMOS)</collab>
            </person-group>
            <article-title>Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS).</article-title>
            <source>J Neurol</source>
            <year>2014</year>
            <month>Jan</month>
            <volume>261</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-16</page-range>
            <pub-id pub-id-type="pmid">24272588</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130642.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jarius</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ruprecht</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Wildemann</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kuempfel</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ringelstein</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Geis</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kleiter</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Kleinschnitz</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Berthele</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Brettschneider</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hellwig</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hemmer</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Linker</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Lauda</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Mayer</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Tumani</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Melms</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Trebst</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Stangel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Marziniak</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hoffmann</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Schippling</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Faiss</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Neuhaus</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Ettrich</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Zentner</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Guthke</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hofstadt-van Oy</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Reuss</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pellkofer</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ziemann</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Kern</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wandinger</surname>
                <given-names>KP</given-names>
              </name>
              <name>
                <surname>Bergh</surname>
                <given-names>FT</given-names>
              </name>
              <name>
                <surname>Boettcher</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Langel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Liebetrau</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rommer</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Niehaus</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>M&#x000fc;nch</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Winkelmann</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zettl U</surname>
                <given-names>UK</given-names>
              </name>
              <name>
                <surname>Metz</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Veauthier</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sieb</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Wilke</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hartung</surname>
                <given-names>HP</given-names>
              </name>
              <name>
                <surname>Aktas</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Paul</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients.</article-title>
            <source>J Neuroinflammation</source>
            <year>2012</year>
            <month>Jan</month>
            <day>19</day>
            <volume>9</volume>
            <fpage>14</fpage>
            <pub-id pub-id-type="pmid">22260418</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130642.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wingerchuk</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Hogancamp</surname>
                <given-names>WF</given-names>
              </name>
              <name>
                <surname>O'Brien</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Weinshenker</surname>
                <given-names>BG</given-names>
              </name>
            </person-group>
            <article-title>The clinical course of neuromyelitis optica (Devic's syndrome).</article-title>
            <source>Neurology</source>
            <year>1999</year>
            <month>Sep</month>
            <day>22</day>
            <volume>53</volume>
            <issue>5</issue>
            <fpage>1107</fpage>
            <page-range>1107-14</page-range>
            <pub-id pub-id-type="pmid">10496275</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130642.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Okada</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kobata</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Naruke</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Neuromyelitis optica spectrum disorder with area postrema syndrome.</article-title>
            <source>Neurol Clin Pract</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>9</volume>
            <issue>2</issue>
            <fpage>173</fpage>
            <page-range>173-175</page-range>
            <pub-id pub-id-type="pmid">31041136</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130642.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lennon</surname>
                <given-names>VA</given-names>
              </name>
              <name>
                <surname>Kryzer</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Pittock</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Verkman</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Hinson</surname>
                <given-names>SR</given-names>
              </name>
            </person-group>
            <article-title>IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel.</article-title>
            <source>J Exp Med</source>
            <year>2005</year>
            <month>Aug</month>
            <day>15</day>
            <volume>202</volume>
            <issue>4</issue>
            <fpage>473</fpage>
            <page-range>473-7</page-range>
            <pub-id pub-id-type="pmid">16087714</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130642.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weinshenker</surname>
                <given-names>BG</given-names>
              </name>
              <name>
                <surname>Wingerchuk</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>Neuromyelitis Spectrum Disorders.</article-title>
            <source>Mayo Clin Proc</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>92</volume>
            <issue>4</issue>
            <fpage>663</fpage>
            <page-range>663-679</page-range>
            <pub-id pub-id-type="pmid">28385199</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130642.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barnett</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Sutton</surname>
                <given-names>IJ</given-names>
              </name>
              <name>
                <surname>Ghadiri</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Masters</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zivadinov</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Barnett</surname>
                <given-names>MH</given-names>
              </name>
            </person-group>
            <article-title>Conventional and advanced imaging in neuromyelitis optica.</article-title>
            <source>AJNR Am J Neuroradiol</source>
            <year>2014</year>
            <month>Aug</month>
            <volume>35</volume>
            <issue>8</issue>
            <fpage>1458</fpage>
            <page-range>1458-66</page-range>
            <pub-id pub-id-type="pmid">23764723</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130642.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sarbu</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Shih</surname>
                <given-names>RY</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>RV</given-names>
              </name>
              <name>
                <surname>Horkayne-Szakaly</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Oleaga</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Smirniotopoulos</surname>
                <given-names>JG</given-names>
              </name>
            </person-group>
            <article-title>White Matter Diseases with Radiologic-Pathologic Correlation.</article-title>
            <source>Radiographics</source>
            <year>2016</year>
            <season>Sep-Oct</season>
            <volume>36</volume>
            <issue>5</issue>
            <fpage>1426</fpage>
            <page-range>1426-47</page-range>
            <pub-id pub-id-type="pmid">27618323</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130642.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Romeo</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Segal</surname>
                <given-names>BM</given-names>
              </name>
            </person-group>
            <article-title>Treatment of neuromyelitis optica spectrum disorders.</article-title>
            <source>Curr Opin Rheumatol</source>
            <year>2019</year>
            <month>May</month>
            <volume>31</volume>
            <issue>3</issue>
            <fpage>250</fpage>
            <page-range>250-255</page-range>
            <pub-id pub-id-type="pmid">30920972</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130642.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wingerchuk</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>Evidence for humoral autoimmunity in neuromyelitis optica.</article-title>
            <source>Neurol Res</source>
            <year>2006</year>
            <month>Apr</month>
            <volume>28</volume>
            <issue>3</issue>
            <fpage>348</fpage>
            <page-range>348-53</page-range>
            <pub-id pub-id-type="pmid">16687064</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130642.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gold</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Linington</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Devic's disease: bridging the gap between laboratory and clinic.</article-title>
            <source>Brain</source>
            <year>2002</year>
            <month>Jul</month>
            <volume>125</volume>
            <issue>Pt 7</issue>
            <fpage>1425</fpage>
            <page-range>1425-7</page-range>
            <pub-id pub-id-type="pmid">12076994</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130642.r22">
          <label>22</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Simakurthy</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tripathy</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <chapter-title>Marcus Gunn Pupil</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>25</day>
            <pub-id pub-id-type="pmid">32491607</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130642.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Patterson</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Goglin</surname>
                <given-names>SE</given-names>
              </name>
            </person-group>
            <article-title>Neuromyelitis Optica.</article-title>
            <source>Rheum Dis Clin North Am</source>
            <year>2017</year>
            <month>Nov</month>
            <volume>43</volume>
            <issue>4</issue>
            <fpage>579</fpage>
            <page-range>579-591</page-range>
            <pub-id pub-id-type="pmid">29061244</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130642.r24">
          <label>24</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Ruia</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tripathy</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <chapter-title>Humphrey Visual Field</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>25</day>
            <pub-id pub-id-type="pmid">36256759</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130642.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>de Seze</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Blanc</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Jeanjean</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Z&#x000e9;phir</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Labauge</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bouyon</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ballonzoli</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Castelnovo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Fleury</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Defoort</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Vermersch</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Speeg</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Optical coherence tomography in neuromyelitis optica.</article-title>
            <source>Arch Neurol</source>
            <year>2008</year>
            <month>Jul</month>
            <volume>65</volume>
            <issue>7</issue>
            <fpage>920</fpage>
            <page-range>920-3</page-range>
            <pub-id pub-id-type="pmid">18625858</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130642.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nakamura</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Misu</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Fujihara</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Miyazawa</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Nakashima</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Takahashi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Watanabe</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Itoyama</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Occurrence of acute large and edematous callosal lesions in neuromyelitis optica.</article-title>
            <source>Mult Scler</source>
            <year>2009</year>
            <month>Jun</month>
            <volume>15</volume>
            <issue>6</issue>
            <fpage>695</fpage>
            <page-range>695-700</page-range>
            <pub-id pub-id-type="pmid">19435750</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130642.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Paul</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Lana-Peixoto</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Tenembaum</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Asgari</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Palace</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Klawiter</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Sato</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>de Seze</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wuerfel</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Banwell</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Villoslada</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Saiz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fujihara</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SH</given-names>
              </name>
              <collab>Guthy-Jackson Charitable Foundation NMO International Clinical Consortium &#x00026; Biorepository</collab>
            </person-group>
            <article-title>MRI characteristics of neuromyelitis optica spectrum disorder: an international update.</article-title>
            <source>Neurology</source>
            <year>2015</year>
            <month>Mar</month>
            <day>17</day>
            <volume>84</volume>
            <issue>11</issue>
            <fpage>1165</fpage>
            <page-range>1165-73</page-range>
            <pub-id pub-id-type="pmid">25695963</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130642.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Huh</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Hyun</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Jeong</surname>
                <given-names>IH</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Cho</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>HJ</given-names>
              </name>
            </person-group>
            <article-title>Cerebral Cortex Involvement in Neuromyelitis Optica Spectrum Disorder.</article-title>
            <source>J Clin Neurol</source>
            <year>2016</year>
            <month>Apr</month>
            <volume>12</volume>
            <issue>2</issue>
            <fpage>188</fpage>
            <page-range>188-93</page-range>
            <pub-id pub-id-type="pmid">26833983</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130642.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>XF</given-names>
              </name>
              <name>
                <surname>Jung</surname>
                <given-names>IJ</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>HJ</given-names>
              </name>
            </person-group>
            <article-title>Does interferon beta treatment exacerbate neuromyelitis optica spectrum disorder?</article-title>
            <source>Mult Scler</source>
            <year>2012</year>
            <month>Oct</month>
            <volume>18</volume>
            <issue>10</issue>
            <fpage>1480</fpage>
            <page-range>1480-3</page-range>
            <pub-id pub-id-type="pmid">22354738</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130642.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Min</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>KH</given-names>
              </name>
            </person-group>
            <article-title>Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder.</article-title>
            <source>Mult Scler</source>
            <year>2012</year>
            <month>Jan</month>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>113</fpage>
            <page-range>113-5</page-range>
            <pub-id pub-id-type="pmid">22146605</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130642.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jacob</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hutchinson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Elsone</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kelly</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ali</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Saukans</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Tubridy</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Boggild</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Does natalizumab therapy worsen neuromyelitis optica?</article-title>
            <source>Neurology</source>
            <year>2012</year>
            <month>Sep</month>
            <day>04</day>
            <volume>79</volume>
            <issue>10</issue>
            <fpage>1065</fpage>
            <page-range>1065-6</page-range>
            <pub-id pub-id-type="pmid">22914835</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130642.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dutra</surname>
                <given-names>BG</given-names>
              </name>
              <name>
                <surname>da Rocha</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Nunes</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Maia</surname>
                <given-names>ACM</given-names>
              </name>
            </person-group>
            <article-title>Neuromyelitis Optica Spectrum Disorders: Spectrum of MR Imaging Findings and Their Differential Diagnosis.</article-title>
            <source>Radiographics</source>
            <year>2018</year>
            <season>Jan-Feb</season>
            <volume>38</volume>
            <issue>1</issue>
            <fpage>169</fpage>
            <page-range>169-193</page-range>
            <pub-id pub-id-type="pmid">29320331</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130642.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zalewski</surname>
                <given-names>NL</given-names>
              </name>
              <name>
                <surname>Morris</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>Weinshenker</surname>
                <given-names>BG</given-names>
              </name>
              <name>
                <surname>Lucchinetti</surname>
                <given-names>CF</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Pittock</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Krecke</surname>
                <given-names>KN</given-names>
              </name>
              <name>
                <surname>Kaufmann</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Wingerchuk</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Flanagan</surname>
                <given-names>EP</given-names>
              </name>
            </person-group>
            <article-title>Ring-enhancing spinal cord lesions in neuromyelitis optica spectrum disorders.</article-title>
            <source>J Neurol Neurosurg Psychiatry</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>88</volume>
            <issue>3</issue>
            <fpage>218</fpage>
            <page-range>218-225</page-range>
            <pub-id pub-id-type="pmid">27913626</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130642.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pearce</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Neuromyelitis optica.</article-title>
            <source>Spinal Cord</source>
            <year>2005</year>
            <month>Nov</month>
            <volume>43</volume>
            <issue>11</issue>
            <fpage>631</fpage>
            <page-range>631-4</page-range>
            <pub-id pub-id-type="pmid">15968305</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130642.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>G&#x000f3;mez-Figueroa</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Alvarado-Bola&#x000f1;os</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Garc&#x000ed;a-Estrada</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zabala-&#x000c1;ngeles</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>S&#x000e1;nchez-Rosales</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Bribiesca-Contreras</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Garc&#x000ed;a-Alvarez</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Montes-P&#x000e9;rez</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ramos-Vega</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Casallas-Vanegas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Carrillo-Loza</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Corona-V&#x000e1;zquez</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Rivas-Alonso</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Flores-Rivera</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Clinical experience of plasmapheresis for neuromyelitis optica patients in Mexico.</article-title>
            <source>Mult Scler Relat Disord</source>
            <year>2021</year>
            <month>Jul</month>
            <volume>52</volume>
            <fpage>103022</fpage>
            <pub-id pub-id-type="pmid">34034213</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130642.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Tian</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Fan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Xiu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Jia</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Shi</surname>
                <given-names>FD</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>Intravenous immunoglobulin for acute attacks in neuromyelitis optica spectrum disorders (NMOSD).</article-title>
            <source>Mult Scler Relat Disord</source>
            <year>2020</year>
            <month>Sep</month>
            <volume>44</volume>
            <fpage>102325</fpage>
            <pub-id pub-id-type="pmid">32653803</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130642.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mealy</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Wingerchuk</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Palace</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Greenberg</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy.</article-title>
            <source>JAMA Neurol</source>
            <year>2014</year>
            <month>Mar</month>
            <volume>71</volume>
            <issue>3</issue>
            <fpage>324</fpage>
            <page-range>324-30</page-range>
            <pub-id pub-id-type="pmid">24445513</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130642.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Agasing</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Quinn</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Axtell</surname>
                <given-names>RC</given-names>
              </name>
            </person-group>
            <article-title>Interferon-&#x003b2; Intensifies Interleukin-23-Driven Pathogenicity of T Helper Cells in Neuroinflammatory Disease.</article-title>
            <source>Cells</source>
            <year>2021</year>
            <month>Aug</month>
            <day>20</day>
            <volume>10</volume>
            <issue>8</issue>
            <pub-id pub-id-type="pmid">34440908</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130642.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hegen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Reindl</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Recent developments in MOG-IgG associated neurological disorders.</article-title>
            <source>Ther Adv Neurol Disord</source>
            <year>2020</year>
            <volume>13</volume>
            <fpage>1756286420945135</fpage>
            <pub-id pub-id-type="pmid">33029200</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130642.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Huda</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Whittam</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bhojak</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chamberlain</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Noonan</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Jacob</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Neuromyelitis optica spectrum disorders.</article-title>
            <source>Clin Med (Lond)</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>19</volume>
            <issue>2</issue>
            <fpage>169</fpage>
            <page-range>169-176</page-range>
            <pub-id pub-id-type="pmid">30872305</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130642.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sellner</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Boggild</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Clanet</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hintzen</surname>
                <given-names>RQ</given-names>
              </name>
              <name>
                <surname>Illes</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Montalban</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Du Pasquier</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Polman</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Sorensen</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Hemmer</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>EFNS guidelines on diagnosis and management of neuromyelitis optica.</article-title>
            <source>Eur J Neurol</source>
            <year>2010</year>
            <month>Aug</month>
            <volume>17</volume>
            <issue>8</issue>
            <fpage>1019</fpage>
            <page-range>1019-32</page-range>
            <pub-id pub-id-type="pmid">20528913</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
